Abstract
Oral cancer is one of the most common malignancies worldwide. The treatment options remain to be surgery, radiation, and/or chemotherapy. In spite of all modern technologies and advances in research, the survival rate of patients with oral cancer has not improved. Among the various chemotherapeutic agents, cisplatin is a commonly used drug for oral squamous cell carcinoma as induction, adjuvant, neoadjuvant, or palliative chemotherapy. This article reviews on the clinical trials done with cisplatin for oral cancer. Based on the review, it is suggestive that cisplatin is superior to other chemotherapy agent, but there is no advantage of cisplatin when used as an adjuvant or neoadjuvant therapy to surgery.
| Original language | English |
|---|---|
| Pages (from-to) | 39-42 |
| Number of pages | 4 |
| Journal | Journal of Advanced Pharmacy Education and Research |
| Volume | 7 |
| Issue number | 2 |
| State | Published - 1 Apr 2017 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Chemotherapy
- Cisplatin
- Oral squamous cell carcinoma
Fingerprint
Dive into the research topics of 'Role of cisplatin in oral squamous cell carcinoma - A review'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver